Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The outcomes of patients treated with cytotoxic or targeted systemic therapy is not well defined for cutaneous squamous cell carcinoma of the head and neck (cSCCHN). Methods: Patients with cSCCHN treated with cytotoxic or targeted systemic therapy were included. Patients were divided into two groups based on the presence of distant metastasis (M1 vs. M0) at presentation. A proportional hazards model was used to assess for independent predictors of overall survival. Results: Of 129 patients with cSCCHN, 20 (16%) were M1 and 109 (84%) were M0. Independent predictors of improved survival were M0 status, treatment of locally advanced disease with radiotherapy, and lower Eastern Cooperative Oncology Group (ECOG) score. Conclusions: Survival was worse in M1 patients treated with cytotoxic or targeted systemic therapy and poor baseline performance status but improved in those receiving radiotherapy. These data can serve as historical controls for future systemic therapy trials, including immunotherapy.

Original languageEnglish (US)
Pages (from-to)1592-1603
Number of pages12
JournalHead and Neck
Volume43
Issue number5
DOIs
StatePublished - May 2021

Keywords

  • chemotherapy
  • head and neck neoplasms
  • skin neoplasms
  • squamous cell carcinoma
  • systemic therapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck'. Together they form a unique fingerprint.

Cite this